Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
Sponsor: ReAlta Life Sciences, Inc.
Summary
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.
Official title: A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia With Long-Term Follow-Up
Key Details
Gender
All
Age Range
Any - 10 Hours
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2023-07-27
Completion Date
2026-04
Last Updated
2025-10-24
Healthy Volunteers
No
Conditions
Interventions
RLS-0071
RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
Placebo
Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
Locations (15)
Study Site 016
Little Rock, Arkansas, United States
Study Site 013
Orange, California, United States
Study Site 020
San Diego, California, United States
Study Site 019
San Diego, California, United States
Study Site 001
Gainesville, Florida, United States
Study Site 018
Miami, Florida, United States
Study Site 010
Orlando, Florida, United States
Study Site 014
Indianapolis, Indiana, United States
Study Site 012
Lexington, Kentucky, United States
Study Site 002
Boston, Massachusetts, United States
Study Site 006
St Louis, Missouri, United States
Study Site 003
Durham, North Carolina, United States
Study Site 021
Cleveland, Ohio, United States
Study Site 022
Fort Worth, Texas, United States
Study Site 005
Morgantown, West Virginia, United States